8-KShareholder Matters

Merck & Co., Inc. 8-K Report, Shareholder Vote Results (May 25, 2012)

Filed May 25, 2012For Securities:MRK

Summary

This Form 8-K report from Merck & Co., Inc. (MRK) filed on May 25, 2012, details the outcomes of its Annual Meeting of Shareholders held on May 22, 2012. The primary focus of the report is the voting results on several key proposals, including the election of directors, ratification of the independent auditor, and advisory votes on executive compensation and shareholder proposals. For investors, the results indicate strong shareholder support for the incumbent board of directors and the company's auditor. The advisory vote on executive compensation also passed overwhelmingly. However, two shareholder proposals, one concerning shareholder action by written consent and another regarding special shareholder meetings, failed to gain majority support. A proposal requesting a report on charitable and political contributions also saw significant opposition. Overall, the voting outcomes suggest continued confidence in the current management and board.

Key Highlights

  • 1All nominated directors were re-elected with substantial "For" votes, indicating shareholder confidence in the board's leadership.
  • 2PricewaterhouseCoopers LLP was ratified as Merck's independent registered public accounting firm for 2012 with overwhelming support.
  • 3Shareholders provided advisory approval for the executive compensation of Named Executive Officers, with a significant majority voting in favor.
  • 4A shareholder proposal seeking the ability for shareholders to act by written consent was not approved.
  • 5Another shareholder proposal advocating for special shareholder meetings also failed to pass.
  • 6A proposal requesting a report on charitable and political contributions was overwhelmingly voted against.

Frequently Asked Questions

The key outcomes included the re-election of all nominated directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and advisory approval of executive compensation. Several shareholder proposals, including those related to written consent and special meetings, did not pass.

All directors nominated for re-election received a strong majority of "For" votes, with millions of votes cast in favor of each nominee, indicating widespread shareholder support for the current board.

Shareholders voted overwhelmingly in favor of approving, by a non-binding advisory vote, the executive compensation of Merck's Named Executive Officers. This suggests general satisfaction with the company's compensation practices at the time.

While two shareholder proposals concerning shareholder action by written consent and special shareholder meetings did not pass, they did receive millions of "For" votes, indicating a segment of shareholders were interested in these governance changes. The proposal regarding charitable and political contributions, however, received very little support.